Page 1

ANTERIS ASX ANNOUNCEMENT 28 October 2021 QUARTERLY ACTIVITY REPORT FOR THE PERIOD TO 30 SEPTEMBER 2021 Brisbane , Australia and Minneapolis , USA . Anteris Technologies Ltd ( ASX : AVR ) ( Anteris or the Company ) releases its Appendix 4C - Quarterly Cash Flow report for the quarter ended 30 September 2021 ( Q3 , 2021 ) . Highlights Material progress towards its proposed FDA early feasibility study submission with multiple mandated pre - clinical trials concluded . World renowned interventional cardiologist , Dr Chris Meduri MD MPH , appointed as Chief Medical Officer to lead clinical progress of DurAVRTM THV System . Manufacturing breakthrough with the development of world - first , specialised machinery leveraging an innovative processing technique for producing the tissue used for ADAPTⓇ treated products . Manufacturing agreement for CardioCel ™ and VascuCel ™ with LeMaitre extended until July 2023 delivering additional ongoing revenue generation . COMMENTARY ON THE QUARTER During the quarter , Anteris made significant progress towards its proposed FDA clinical study with further validation of its heart valve focused ADAPT® , DurAVR ™ and ComASUR ™ products . The Company appointed internationally recognised Interventional Cardiologist , Dr Chris Meduri MD MPH , as its Chief Medical Officer in September 2021 , to help guide its clinical programme . Dr Meduri is a recognised leader in the field of valvular heart disease , serving as the national principal investigator of several valve trials and on numerous steering committees where he had an instrumental role in researching , clinically validating and commercialising novel and innovative heart products . Anteris ' made a manufacturing breakthrough with the tissue used in ADAPTⓇ treated products from bovine pericardium . It developed world - first , proprietary machinery capable of creating consistently thin tissue via an innovative processing technique . This technique reduces the native pericardia thickness to yield precise tissue used to make the Company's 3D single - piece aortic valves . Additionally , the Company extended its manufacturing agreement for CardioCel ™ and VascuCel ™ with LeMaitre Vascular Inc at its Malaga facility in Western Australia an additional nine - months . The manufacturing contract will now conclude in July 2023 . Anteris Technologies Ltd Registered Office : Toowong Tower , Suite 302 , Level 3 , 9 Sherwood Rd , Toowong , Queensland , 4066 Customer Service T +61 1300 550 310 | F +61 1300 972 437 | E info@anteristech.com | W anteristech.com Brisbane ▪ Minneapolis ▪Geneva ▪ Malaga ADAPT for life